Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
Associated Therapies
-

The Appropriate Anticoagulation Duration for Chronic Obstructive Pulmonary Disease With Pulmonary Thromboembolism

First Posted Date
2017-06-14
Last Posted Date
2017-06-14
Lead Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Target Recruit Count
392
Registration Number
NCT03185845
Locations
🇨🇳

Beijing Chaoyang Hospital, Beijing, Beijing, China

Dabigatran in Patients With Atrial Fibrillation and Mitral Biological Prostheses

First Posted Date
2017-06-12
Last Posted Date
2017-06-12
Lead Sponsor
Research Institute for Complex Problems of Cardiovascular Diseases, Russia
Target Recruit Count
40
Registration Number
NCT03183843
Locations
🇷🇺

Research Institute for Complex Problems of Cardiovascular Diseases, Kemerovo, Russian Federation

Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants

First Posted Date
2017-06-08
Last Posted Date
2022-06-15
Lead Sponsor
University of Sao Paulo General Hospital
Target Recruit Count
60
Registration Number
NCT03181386
Locations
🇧🇷

Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

Start or STop Anticoagulants Randomised Trial (SoSTART)

First Posted Date
2017-05-15
Last Posted Date
2022-04-08
Lead Sponsor
University of Edinburgh
Target Recruit Count
203
Registration Number
NCT03153150
Locations
🇬🇧

Frimley Park Hospital, Frimley, United Kingdom

🇬🇧

Gloucestershire Royal Hospital, Gloucester, United Kingdom

🇬🇧

Pinderfields Hospital, Wakefield, United Kingdom

and more 64 locations

Anticoagulation Therapy in the Very Old

Completed
Conditions
Interventions
First Posted Date
2017-04-06
Last Posted Date
2021-08-17
Lead Sponsor
Robert Stein
Target Recruit Count
132
Registration Number
NCT03103763
Locations
🇺🇸

Penobscot Bay Medical Center, Rockport, Maine, United States

MAGENTUM 1 HeartMate 3 LVAS: A Single Center Prospective Controlled Study (MAGENTUM 1)

Not Applicable
Conditions
Interventions
First Posted Date
2017-03-13
Last Posted Date
2020-08-04
Lead Sponsor
Institute for Clinical and Experimental Medicine
Target Recruit Count
15
Registration Number
NCT03078374

Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation

First Posted Date
2017-02-23
Last Posted Date
2021-09-02
Lead Sponsor
Intermountain Health Care, Inc.
Target Recruit Count
101
Registration Number
NCT03061006
Locations
🇺🇸

Intermountain Heart Institute, Murray, Utah, United States

Validation of Predictors of OAC Initiation Using EMR Data

First Posted Date
2016-12-30
Last Posted Date
2019-03-22
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
140187
Registration Number
NCT03006341
Locations
🇺🇸

Brigham & Women's Hospital, Boston, Massachusetts, United States

Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease

First Posted Date
2016-12-06
Last Posted Date
2021-01-13
Lead Sponsor
Asan Medical Center
Target Recruit Count
120
Registration Number
NCT02982850
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus

First Posted Date
2016-12-05
Last Posted Date
2021-07-08
Lead Sponsor
Universiti Sains Malaysia
Target Recruit Count
27
Registration Number
NCT02982590
Locations
🇲🇾

Hospital Universiti Sains Malaysia, Kota Bharu, Kelanatan, Malaysia

© Copyright 2024. All Rights Reserved by MedPath